Largest provider of biopharmaceutical development and commercial outsourcing services.

Learn More About Quintiles

Highly selective medicines for genomically defined cancers.

Aisling congratulates the management team of Loxo on its recent acquisition by Eli Lilly.

Learn More About Loxo

Developing late-stage neuroscience compounds targeting migraine and psychiatric disorders.

Learn More About Biohaven

Novel treatments for people living with narcolepsy and other central nervous system disorders.

Learn More About Harmony

CoolSculpting®: more science, less fat.

Aisling congratulates the management team of Zeltiq on its recent acquisition by Allergan.

Learn More About ZELTIQ

Developing Treatments for Food Allergies Using Standardized, Pharmaceutical-Grade Food Allergens and Characterized Oral Desensitization Immunotherapy

Learn More About Aimmune

Aimmune

Loxo

Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

Learn More

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

Learn More

Latest News

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

May 12, 2026

Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 All...

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher

April 24, 2026

Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory...

BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma

April 20, 2026

BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumorsUpdated Phase 1 clinical data are expected in the...

more news